Becton, Dickinson and Company (NYSE:BDX) Shares Purchased by Cypress Capital Group

Cypress Capital Group raised its holdings in Becton, Dickinson and Company (NYSE:BDX) by 9.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,948 shares of the medical instruments supplier’s stock after acquiring an additional 350 shares during the quarter. Cypress Capital Group’s holdings in Becton, Dickinson and Company were worth $923,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in BDX. Livelsberger Financial Advisory purchased a new position in Becton, Dickinson and Company in the 4th quarter worth about $27,000. OLD Point Trust & Financial Services N A purchased a new position in shares of Becton, Dickinson and Company in the fourth quarter worth approximately $29,000. DiNuzzo Private Wealth Inc. acquired a new stake in shares of Becton, Dickinson and Company during the fourth quarter valued at approximately $30,000. Scarborough Advisors LLC purchased a new stake in shares of Becton, Dickinson and Company in the 4th quarter valued at approximately $32,000. Finally, Rise Advisors LLC acquired a new position in Becton, Dickinson and Company in the 1st quarter worth approximately $38,000. Institutional investors own 86.97% of the company’s stock.

Insider Buying and Selling

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 300 shares of the company’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $239.31, for a total transaction of $71,793.00. Following the completion of the sale, the senior vice president now directly owns 1,976 shares in the company, valued at $472,876.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.7 %

Shares of Becton, Dickinson and Company stock traded up $1.77 during midday trading on Monday, reaching $238.15. 112,431 shares of the company’s stock traded hands, compared to its average volume of 1,425,758. The company has a market cap of $68.83 billion, a price-to-earnings ratio of 52.07, a price-to-earnings-growth ratio of 2.06 and a beta of 0.42. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $283.50. The company’s 50 day simple moving average is $233.26 and its 200 day simple moving average is $236.07. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.97 and a current ratio of 1.85.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The company had revenue of $4.99 billion during the quarter, compared to analysts’ expectations of $5.08 billion. During the same quarter in the previous year, the firm earned $2.96 earnings per share. The business’s quarterly revenue was up 2.3% compared to the same quarter last year. Equities analysts expect that Becton, Dickinson and Company will post 13.06 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be issued a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a dividend yield of 1.60%. The ex-dividend date of this dividend is Monday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 83.70%.

Analyst Ratings Changes

BDX has been the subject of a number of research analyst reports. Barclays increased their target price on Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a report on Monday, May 6th. Citigroup lowered their target price on Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 10th. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Evercore ISI lowered their price objective on shares of Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. Finally, The Goldman Sachs Group started coverage on shares of Becton, Dickinson and Company in a research report on Thursday, May 30th. They issued a “buy” rating and a $274.00 target price for the company. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company has an average rating of “Moderate Buy” and an average target price of $279.50.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.